Bayer, Versant Invest $225M In Stem Cell Venture
In one of the largest-ever series A financings for a biotech company, Bayer AG and Versant Ventures Inc. announced Monday they have committed $225 million to create a joint venture to...To view the full article, register now.
Already a subscriber? Click here to view full article